Test medicine for aggressive brain tumor using a five-drug combo
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests ERC1671 together with four other medicines to treat recurrent or worsening glioblastoma (a WHO grade IV brain cancer). It aims to slow tumor growth and improve outcomes after the tumor comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have a confirmed recurrent or progressive glioblastoma (WHO grade IV).
- You can have an MRI with contrast and your scans can be scheduled around prior surgery and radiation timing.
- Your general strength is reasonably good (KPS 60% or higher) and your estimated life expectancy is more than 12 weeks.
- You’ve already had standard treatment for glioblastoma: surgery, radiation, and temozolomide (TMZ).
- Your blood counts and key organ tests (like kidneys, liver, and CD4 level) meet required minimums.
- You can take study treatment only if prior treatment side effects have mostly improved (to Grade 1 or less, with a few allowed exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
This Phase 2 study tests whether adding recombinant human endostatin to temozolomide and irinotecan can slow or control recurrent gliomas (brain tumors) after prior standard treatment. It may help by targeting tumor blood vessel growth while also using chemotherapy to attack cancer cells.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
Hear when a new Glioma, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.